Recent Finacing
Recent Raise
Abata develops autologous Treg therapies engineered with antigen-specific TCRs to localize immunomodulation, suppress inflammation, and promote repair, with HLA‑restricted programs in MS, T1D, myositis and an ElevateBio manufacturing partnership.
